Site icon pharmaceutical daily

Global Blood-Brain Barrier Market Assessment 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics” report has been added to ResearchAndMarkets.com’s offering.

Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics (2nd Edition) [based on Receptor Mediated Transcytosis, Trojan Horse, and Nanoparticle based Approaches] features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for BBB penetration technologies and affiliated therapeutics, over the next decade. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2020-2030. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity.

The report also features the likely distribution of the current and forecasted opportunity across:

Market Summary and Insights

According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), such as Alzheimer’s disease, brain cancer, multiple sclerosis. Parkinson’s disease and stroke, are characterized by a significant unmet need for effective treatment options. In 2019, it was reported that nearly 1.5 billion people suffer from some form of disorder affecting the CNS across the globe. In fact, the incidence of CNS disorders is anticipated to increase by 12% by 2030. In 2019, nearly 5.8 million Americans were reported to have been diagnosed with Alzheimer’s disease.

Similarly, Parkinson’s disease was estimated to affect nearly one million people in America, with approximately 60,000 new patients being diagnosed every year. Further, experts believe that there is a critical relationship between recent pandemic of novel Coronavirus (COVID-19) and the cardiovascular and cerebrovascular systems. People suffering from certain CNS complications are at a relatively higher risk of COVID-19 infection due to a compromised immune system.

It is estimated that CNS disorders are responsible for a healthcare burden of nearly USD 2 trillion, in the US and Europe. Developing viable therapies against the aforementioned clinical conditions is largely complicated due to the elusive blood-brain barrier (BBB), a selectively permeable structure, which is very effective in preventing the entry of foreign substances, including drugs, into the brain. It has been reported that over 1,000 currently available / under development drugs targeting CNS disorders do not have the potential to target specific brain receptors responsible for the disease progression due to the hindrance by the BBB. Considering the serious physical, cognitive and psychosocial consequences that such indications have on patients, coupled to the alarming increase in their global prevalence, there is an urgent need for novel and effective treatment options that can cross the BBB.

Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the BBB or augment the BBB penetrating capabilities of compatible pharmacological interventions. As a result, presently, there is a lot of enthusiasm within the medical science community related to these technologies.

The growing interest in this field is also evident in the fact that over 1,200 modern scientific articles have been published (as observed on NCBI’s PubMed portal) over the last three years alone. However, it is worth mentioning that there are currently no approved BBB penetrating drugs available in the market. Currently, this niche market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines. In fact, over the last 4-5 years, there has been a marked rise in the number of new entrants in this field. We anticipate this upcoming market to witness substantial growth in the coming years.

In addition to other elements, the study includes:

In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

Key Questions Answered

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/uv68bx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version